Syros Announces Closing of Concurrent Public Offerings
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
Syros Pharmaceuticals (SYRS) PT Lowered to $24 at Piper Jaffray
April 10, 2019 9:19 AM EDTPiper Jaffray analyst Edward Tenthoff lowered the price target on Syros Pharmaceuticals (NASDAQ: SYRS) to $24.00 (from $28.00) while maintaining a Overweight rating. Syros recently raised gross proceeds of $70 million, bringing estimated pro forma cash to ~$165 million.
Syros is developing potentially best-in-class CDK7 inhibitors.... More
